The combination of PTEN loss, with additional deletions or mutations of RB1 and TP53 have also been shown to harbor the onset metastatic castration resistant PCa (mCRPC) phenotypes in both human samples and genetically engineered mouse models. This evidence concerns the gene PTEN and posterior cortical atrophy.